Scribe Therapeutics Awarded More Than $25 Million From CIRM to Accelerate Additional CRISPR-Based Gene Editing

The targets: LPA and APOC3

STX-1200 is engineered to lower lipoprotein(a), or Lp(a)—a particle almost entirely determined by heredity and largely unresponsive to statins or PCSK9 inhibitors. According to figures cited in Scribe's announcement, elevated Lp(a) affects roughly one in five people globally and is associated with a two-to-four-fold increase in premature myocardial infarction and aortic stenosis. STX-1400, the parallel program, targets *APOC3* to reduce triglyceride-rich lipoproteins, with stated indications in acute pancreatitis driven by severe hypertriglyceridemia, including familial and multifactorial chylomicronemia syndromes. Both candidates share the same XE editing scaffold, which the company describes as optimized for activity, specificity, and deliverability in vivo.

The platform question

We observe in the data that the longevity-relevant variable is not the indication but the editing chemistry itself. A single validated in vivo CRISPR platform, demonstrated to produce stable on-target edits with acceptable off-target profiles, could plausibly be redeployed across additional cardiometabolic and aging-related targets. Conversely, a platform that performs in rodents but falters on delivery efficiency, immunogenicity, or durability in primates will not translate, regardless of which gene it is aimed at. CIRM's preclinical awards fund the IND-enabling work that determines which of those two outcomes the data support.

Evidence limits and what to track

Two preclinical grants are not clinical evidence. The awards support the transition toward first-in-human trials; they do not establish efficacy, long-term durability of editing, or the off-target profile that will ultimately determine the therapeutic window. The relevant checkpoints for this cohort are: regulatory clearance to dose, initial safety and biomarker readouts (Lp(a) and triglyceride reductions quantified at durable time points), and any hepatic or vascular signals of concern. Until those data land, the mechanistic rationale is coherent, but the clinical claim remains preclinical.

Practical layer for now

Until gene editing changes the measurement landscape, the actionable step is conventional: Lp(a) is not part of a standard lipid panel, so it requires a separate assay. Readers with a family history of premature cardiovascular events may want to discuss Lp(a) testing and cascade screening with a clinician, as a confirmed elevated level materially changes long-term risk stratification and may eventually determine candidacy for the very therapies now in preclinical development.